Low-Dose Oral Minoxidil (LDOM) for Telogen Effluvium
Verdict: Published with Warning
Across 5 PubMed studies, the evidence for Low-Dose Oral Minoxidil (LDOM) in Telogen Effluvium grades Tier C — weak evidence. Effective, but with safety or population caveats.
C 🟠 C Weak Evidence Published with Warning
Why this grade7-layer evidence engine
⚖️
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditableRaw score 0.67
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published with Warning
Confidence
86%
Highly consistent evidence
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)
▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.667
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 高品質 SR/MA 顯示 positive (2 篇 > 0 negative)
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
PubMed studies (5)L2 · primary research & systematic reviews
Efficacy and safety of oral minoxidil in the treatment of alopecia: a single-arm rate meta-analysis and systematic review
Finding: Across 27 single-arm studies (n=2933), 47% improved (95% CI 38-55%) and 35% had significant improvement (95% CI 22-49%), with a 27% pooled adverse-event rate (95% CI 18-36%); telogen effluvium patients were included in the pooled population but NO telogen-effluvium-specific effect estimate was reported (subgroups were by dose only).
View on PubMed Safety of low-dose oral minoxidil treatment for hair loss. A systematic review and pooled-analysis of individual patient data
Finding: In 442 pooled patients, hypertrichosis occurred in 24%, pedal edema in 2%, postural hypotension in 1.1% and heart-rate changes in 1.3%, with no life-threatening adverse events reported, supporting an acceptable safety profile (efficacy was not the primary endpoint).
View on PubMed Oral minoxidil use in androgenetic alopecia and telogen effluvium
Finding: In a case-matched analysis (105 treated vs 105 controls), 52.4% of treated patients improved and 42.9% stabilized, a significant difference in clinical response vs controls (p<0.001); however telogen-effluvium patients were pooled with AGA and not reported separately.
View on PubMed Treatment of chronic telogen effluvium with oral minoxidil: A retrospective study
Finding: In 36 women with chronic telogen effluvium, mean HSS fell by 1.7 at 6 months and 2.58 at 12 months (both p<0.001); this is the only telogen-effluvium-specific clinical study but it is retrospective, uncontrolled and relies on a subjective shedding score.
View on PubMed Low-Dose Oral Minoxidil for Alopecia: A Comprehensive Review
— See PubMed for details
View on PubMed Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …
L4a US FDA
Cautious
BOXED WARNING: 'Minoxidil tablets contain the powerful antihypertensive agent, minoxidil, which may produce serious adverse effects. It can cause pericardial effusion, occasionally progressing to tamponade, and angina pectoris may be exacerbated. Minoxidil must be administered under close supervision, usually concomitantly with therapeutic doses of a beta-adrenergic blocking agent to prevent ta… source↗
L4b EU EFSA
Cautious
Minoxidil and its salts must not be used in cosmetic products because of their antihypertensive activity. Minoxidil absorption after scalp application could lead to systemic effects. [Minoxidil is] a peripheral vasodilatator acting on vascular smooth muscle cells, used as a drug in the management of severe hypertension. [The substance is] cardiotoxic in long term oral studies. source↗
L4c UK NHS
Cautious
Minoxidil foam (Regain) is the only licensed treatment for female and male pattern hair loss. You will start on a 0.625mg dose on alternate days; any further changes to the dose will be discussed in your follow up consultations. While you are receiving minoxidil treatment you should have your pulse and blood pressure monitored regularly by your GP. This treatment is not advised for individuals … source↗
L4d TW TFDA / 衛福部
Cautious
洛寧錠10毫克 LONITEN 10MG 衛署藥輸字 第 007538 號 須由醫師處方使用；目前口服 minoxidil 的適應症還是只有用在高血壓，用在治療落髮還是屬於適應症外用藥。 source↗
L4e WHO
Neutral
Minoxidil belongs to the drug class of direct-acting peripheral vasodilators. It exerts its antihypertensive effect by opening adenosine triphosphate (ATP)-sensitive potassium channels, thereby reducing peripheral resistance and lowering blood pressure. The FDA approved minoxidil in tablet form in 1979 under the brand name Loniten specifically for treatment of high blood pressure. Low-dose oral… source↗
L5a NIH Office of Dietary Supplements
Cautious
LONITEN (minoxidil tablets) is indicated only in the treatment of hypertension that is symptomatic or associated with target organ damage and is not manageable with maximum therapeutic doses of a diuretic plus two other antihypertensive drugs. Elongation, thickening, and enhanced pigmentation of fine body hair are seen in about 80% of patients taking LONITEN Tablets. This develops within 3 to 6… source↗
L5c Cleveland Clinic
Supportive
The majority of our patients are on it for telogen effluvium, or shedding, and female or male pattern alopecia. We start with 2.5 mg pills and have our patients split them to 0.625 or, more commonly, 1.25 milligrams a day. source↗
L5e Specialty Society (condition-mapped)
Supportive
A growing number of research groups have reported on the off-label use of low-dose oral minoxidil (LDOM), ranging from 0.25 mg to 5 mg daily, as a safe and effective treatment option for male and female patients with AGA, age-related patterned thinning, traction alopecia, alopecia areata, telogen effluvium, scarring, and other forms of hair loss. ... Experts agreed on the direct benefits of low… source↗